Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.
News|Videos|December 23, 2025
Sonrotoclax (BGB-11417) Monotherapy in Patients With R/R MCL Previously Treated With a BTK Inhibitor: Results From a Phase 1/2 Study
Author(s)Luhua (Michael) Wang, MD
Michael Wang, M.D. discusses Sonrotoclax (BGB-11417) monotherapy in patients with R/R MCL previously treated with a BTK inhibitor: results from a phase 1/2 study
Advertisement
Michael Wang, M.D. discusses how, Sonrotoclax monotherapy showed strong and durable clinical activity in heavily pretreated patients with relapsed or refractory mantle cell lymphoma, with consistent benefit across high-risk subgroups. The treatment was generally well tolerated with manageable safety and a low rate of tumor lysis syndrome, supporting its potential as a promising new option in this setting.
Advertisement
Related to this article
Sara Nunnery, MD, MSCI, and Irene M. Kang, MD, discuss toxicity and monitoring considerations for the use of ADCs in metastatic TNBC.
The NMPA accepted the NDA for the PD-L1/4-1BB–directed bispecific antibody opamtistomig in previously treated advanced extrapulmonary NEC.
Obesity can weaken the immune system and lead to disease progression, but Roswell Park experts revealed that exercise may reverse that effect.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The European Commission approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior therapy, offering the regimen as early as second line.
ASCO’s ctDNA guidelines support testing for genetic alterations in select scenarios but do not endorse it for residual disease or recurrence monitoring.
Updated ASCO Living Guideline recommendations expand frontline therapy for HER2-positive gastroesophageal cancer to include zanidatamab-based regimens.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
2
CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma
3
FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma
4
European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma
5